Objectives: To determine the most recent prevalence, transmission patterns and risk factors of transmitted drug-resistance mutations (TDRMs) in Cameroon, we initiated a multicentre study monitoring HIV-1 drug resistance in newly HIV-1-diagnosed individuals using a novel next-generation sequencing (NGS) assay applicable to fingerprick dried blood spot (DBS) samples.
Introduction
Since its implementation, combination ART has greatly reduced the morbidity and mortality caused by HIV-1 infections worldwide. 1 However, this improvement is being hampered by the emergence of drug-resistant viruses, 2 posing a more serious problem today in resource-limited settings compared with resourcerich settings. 3, 4 Acquired HIV-1 drug resistance develops when viral mutations emerge due to viral replication in the presence of insufficient levels of antiretroviral drugs; meanwhile, transmitted HIV-1 drug resistance occurs when individuals are infected with a drug-resistant virus. 5 Also, minority drug-resistant HIV-1 variants, undetected by conventional genotyping may impair the outcome of ART. [6] [7] [8] However, the impact of pre-existing minority drugresistant HIV-1 variants on first-line ART still remains unclear. [9] [10] [11] [12] Cameroon, like many other developing countries, is increasing its HIV prevention and treatment efforts, which has led to the widespread use of ART through national scale-up plans. In 2015, the Joint UN Programme on HIV and AIDS (UNAIDS) estimated the adult HIV-1 prevalence in Cameroon to be 4.5%, with about 620 000 people living with HIV-1. 13 In May 2016, ART eligibility in the country was modified to include all individuals diagnosed with HIV-1 in over 145 treatment centres (HIV Approved Treatment Centres and HIV Management Units) nationwide. In 2013, a survey conducted in 15 HIV-1 treatment centres in Cameroon evaluating HIV-1 drug resistance early warning indicators (EWIs) revealed that only 33.3% of centres reached the desirable performance for 'on-time pill pick-up' while just 14.4% reached the desirable performance of 'no pharmacy stock-outs'.
14 With limited healthcare infrastructure for care and monitoring, Cameroon may face increasing rates of HIV-1 drug resistance in the near future.
Surveillance of transmitted and acquired HIV-1 drug resistance is essential for the management of ART programmes. 5 Recent systematic reviews of published literature between 2014 and 2017 on pretreatment HIV-1 drug resistance in adults from low-and middle-income countries, including Cameroon, found that NNRTI resistance was higher in more recent studies across Eastern Africa, Southern Africa, Western and Central Africa, Latin America and Asia. 4, 15 In Cameroon, very few studies on HIV-1 drug resistance in untreated patients have been conducted so far, and report low to moderate prevalence rates (, 8%) of transmitted drug resistance mutations (TDRMs). [16] [17] [18] These studies were performed with few samples (median 141), targeting special groups of people, such as pregnant women and blood donors, and/or conducted in specific geographical areas, mainly the south-eastern part of the country. Findings from these data are quite useful but a larger and more diverse sample population would better estimate the prevalence of TDRMs in Cameroon. Another unique circumstance in Cameroon is that all major groups and subtypes of HIV-1 co-circulate, 19, 20 which represents a challenge for genotypic HIV-1 drug resistance testing.
Here, we have developed a next-generation sequencing (NGS) assay for genotypic HIV-1 drug resistance testing applicable to dried blood spot (DBS) samples. Using DBS samples overcomes the challenges with handling plasma samples in resource-limited settings. Using this test, we determined the recent prevalence of transmitted HIV-1 drug resistance and its associated risk factors in newly diagnosed patients from the western and northern areas of Cameroon.
Materials and methods

Establishment of the genotypic HIV-1 drug resistance assay
The newly designed genotypic HIV-1 drug-resistance assay, DBS-NGSgenotypic resistance test (DBS-NGS-GRT), encompasses amino acids 1-99 of the HIV-1 protease (PR) and 1-321 of the reverse transcriptase (RT). PR and RT genes are amplified in two fragments, each fragment comprising a semi-nested PCR of cDNA transcribed from RNA. The virus stock HIV-1 NL4-3 subtype B, several primary virus isolates and HIV-1 subtypes A, C, D, G, F and CRF02_AE were used to develop and validate the assay. Details regarding the establishment and validation of our DBS-NGS-GRT assay are described in File S1 (available as Supplementary data at JAC Online).
Study population and data collection
Between April 2015 and July 2016, fingerprick DBS samples were collected from 360 patients in four different hospitals in Cameroon, representing three regions of the country: the North-West (Bamenda Regional Hospital and Ndop District Hospital), South-West (Kumba District Hospital) and Adamawa (Ngaoundere Regional Hospital) regions ( Figure 1a ). Participants had to meet the following inclusion criteria: (i) age 18 years; (ii) newly diagnosed with HIV-1; and (iii) with no previous exposure to any form of ART. The procedure for fingerprick DBS collection and handling was adapted from the WHO manual for HIV drug resistance testing using DBS samples. 21 This manual was distributed to all four hospitals (File S2). A questionnaire capturing patient demographics, clinical data and sexual behaviours was also administered (File S3). The samples and completed questionnaires from all sampling sites were sent at room temperature by express mail to the Division of Infectious Diseases and Hospital Epidemiology of the University Hospital of Zurich in Switzerland, where they were stored at #80 C until further procedures. Details on the handling and shipment of fingerprick DBS samples can be found in File S1.
Ethics statement
This study was approved by the National Ethics Committee of Cameroon (Number: 2015/01/539/CE/CNERSH/SP) and written informed consent was obtained from each participant.
Laboratory methods and data analyses
HIV-1 RNA was isolated from an equivalent of 100 lL of blood (two spots) on a Whatman V R 903 protein saver card (DBS sample). DNase-treated HIV-1 RNA was reverse-transcribed and amplified by two semi-nested PCRs using the primers shown in Table S1 . PCR products were purified, quantified and sequenced with the Illumina MiSeq system. Sequencing reads were retrieved, processed and mutations were called with MinVar (git.io/minvar), a tool to discover and annotate mutations from NGS of HIV-1 populations. 22 Mutations were called with a cut-off of 3% and finally annotated according to the Stanford HIV Drug Resistance Database, 23 version 8.1.1 (https://hivdb.stanford.edu/). The assessment of TDRMs was done using the WHO 2009 list of mutations for surveillance of transmitted drugresistant HIV strains 24 (https://hivdb.stanford.edu/page/who-sdrm-list/). Phylogenetic and statistical analyses were also performed on sequences and questionnaire data. The above methods are described in detail in File S1.
Results
Demographic and baseline characteristics of patients
In total, fingerprick DBS samples were collected from 360 newly diagnosed patients in four hospitals in Cameroon. Three of the hospitals are located in urban areas (sites A, B and D) and one in a semi-urban area (site C; Figure 1a) . From April 2015 until July 2016, 51, 210, 35 and 64 patients were enrolled in the study by the centres A, B, C and D, respectively. DBS samples were obtained from each participant and completed questionnaires were returned by 334 (92.8%) participants (Figure 1b) . In the following analysis, data from patients for whom HIV-1 RNA was successfully amplified and sequenced (n " 298) were included, as well as questionnaire data from patients with HIV-1 sequences (n " 289).
Demographic and clinical baseline data are shown in Establishment and validation of the amplification of HIV-1 RNA from DBS samples
We first developed an amplification protocol applicable to DBS samples for the establishment of a genotypic HIV-1 PR and RT drug resistance assay. This assay is universal, i.e. applicable to all heterogeneous HIV-1 subtypes i.e., applicable to HIV-1 genomes of groups M, N and O. HIV-1 RNA was isolated from an equivalent of 100 lL of blood on a Whatman V R 903 protein saver card, reversetranscribed and amplified by two semi-nested PCRs. To determine the applicability in terms of diverse HIV-1 subtypes and the sensitivity, limited diluted HIV-1-spiked DBS samples (HIV-1 subtypes A, B, C, D, G, F and CRF02_AE) were tested. All these HIV-1 subtypes were successfully amplified with a lower limit of detection of 1000 HIV-1 RNA copies/mL (Table S2 ). The error rates generated by PCR and NGS ranged from 0.04% to 0.66% and were previously investigated using the same reagents and kits that were used in this study. 26 We proceeded to apply our established DBS-NGS-GRT to the 360 patient fingerprick DBS samples. Amplification of HIV-1 PR and/or RT was successful in 298/360 (82.8%) DBS samples ( Figure 1b) . From 240/298 (80.5%) DBS samples, both amplicons were generated, while from 58/298 (19.5%) DBS samples only the RT region was successfully amplified. Investigating the possible reason for amplification failure in 62 DBS samples, we first examined the correlation to the CD4! T cell count measured at the hospitals in Cameroon, i.e. as a surrogate marker for disease progression and viral load. A significantly lower CD4! T cell count (P , 0.0001) was observed for patients whose samples were successfully amplified compared with those whose samples failed amplification ( Figure S1a ). Secondly, we quantified and compared the HIV-1 cDNA copy numbers in DBS samples in those two groups. Successful amplification was significantly associated with higher HIV-1 cDNA copy numbers (P , 0.0001) ( Figure S1b ). The subtype diversity in this study was quite high as all group M HIV-1 subtypes and circulating recombinant forms previously known to exist in Cameroon were detected in patients' samples ( Figure 2c ). In summary, we developed and applied a highly efficient, universal HIV-1 PR and RT amplification procedure for DBS samples.
Prevalence of HIV-1 transmitted drug resistance
Sequence results were obtained from 298 successful amplicons ( Figure 1b) . Overall, TDRMs were found in 31/298 patients (10.4%; 95% CI 7.2%-14.4%). In those individuals, the minimum coverage per nucleotide was 439 (Table 2 ; patient 5) and the minimum HIV-1 cDNA copy number sequenced was 131 copies/5 lL (Table 2 ; patient 22) allowing a cut-off for low-abundance TDRMs at 3%. TDRMs were checked for APOBEC3G/F signatures: no G-to-A hypermutations were detected in the NGS reads.
First, we investigated the prevalence of TDRMs at frequencies .15%, i.e. which would also be detectable by population sequencing commonly performed by Sanger sequencing. In 19/298 patients (6.4%; 95% CI 3.9%-9.8%), TDRMs were detected at frequencies .15% (Figure 2a ). Here, TDRMs to PIs were detected in 3/240 patients (1.3%; 95% CI 0.3%-3.6%), to NRTIs in 9/298 patients (3.0%; 95% CI 1.4%-5.7%) and to NNRTIs in Expanding the analysis to low-abundance TDRMs, i.e. 3%-15%, 12/298 additional individuals (4.0%; 95% CI 2.1%-6.9%) were identified. As observed for high-abundance TDRMs, the majority of low-abundance TDRMs were associated with resistance to NNRTIs (Figure 2b) . Details of the different characteristics, mutation types and their percentage abundance for the 31 individuals with low-and highabundance TDRMs are shown in Table 2 . The most commonly detected TDRM was the K103N mutation: 8/298 patients (2.7%; 95% CI 1.2%-5.2%), in seven of those patients occurring as a highabundance TDRM ( Table 2 ). The M184V mutation was detected in 4/298 patients (1.3%; 95% CI 0.4%-3.4%) at high frequencies and the M184I mutation also in 4/298 patients (1.3%; 95% CI 0.4%-3.4%) at high (n " 3) and low (n " 1) frequencies. One patient harboured both the M184V and M184I mutations ( Table 2) .
The impact of TDRMs on future therapy response in patients was assessed with the scoring system of the Stanford HIV Drug Resistance Database. In 51.6% (16/31; 95% CI 33.1%-69.8%) cases, only low-level or potential low-level resistance was observed. Some patients had a combination of two or three resistance profiles (low, intermediate or high) for different drugs (Table 2) .
Transmission clusters of DRMs were not found within and between study sites
To investigate any transmission clusters of drug resistance in the study population, phylogenetic analysis was performed. From the phylogenetic tree generated with our sequences, together with the background sequences (Figure 3a and File S4), cluster analysis revealed 200 clusters in total (bootstrap values .90%). Twentyfive of these clusters included individuals from our study population. Seventeen of those clusters included more than one individual of our study population. Of these, two clusters had patients with a DRM. One cluster with two study patients was found with both of them having a drug resistance mutation (E138G) (Figure 3b) . Another cluster had two study patients with one of them having a DRM (M46I) (Figure 3c ).
Comparison of demographic, clinical and risky sexual parameters between individuals with and without TDRMs
Besides acquiring patients' clinical and demographic data, the questionnaire also sought to examine the sexual attitudes of patients for any risky behaviours before HIV-1 diagnosis. This analysis could only be performed for the 289 patients with returned questionnaires and NGS data, out of the 298 patients with successfully amplified and sequenced samples, leaving out 9 patients with NGS data but no questionnaires (Table 1 ). There was a significant difference in the number of patients with and without TDRMs between the study sites, with site B having the highest frequency of patients with TDRMs. We found a statistically significant difference (MannWhitney U-test P " 0.0006) between the cDNA copy numbers for both groups (with and without TDRMs) but this difference became not significant once we excluded data from patients with lowabundance TDRMs. In a univariable logistic regression, it was found that having unprotected sex with a known HIV-1-positive person was significantly associated with the transmission of DRMs [OR 9.1 (95% CI 1.75-47.2, P " 0.009)]. In a multivariable logistic 
Discussion
We have developed a sensitive, specific and universal assay for the determination of HIV-1 drug resistance using DBS samples and applying NGS, suitable for up to 96 samples per MiSeq flow cell. DBS samples serve as an attractive sampling alternative to plasma especially in developing countries (resource-limited), overcoming the challenges that come with handling plasma, such as successfully maintaining the cold chain at #80 C. Our DBS-NGS-GRT was designed taking into account the very high HIV-1 subtype distribution in Central Africa. The primers were carefully designed to cover all major HIV-1 group M subtypes and circulating recombinant forms (CRFs) as well. The overlapping amplicon strategy used in the PCRs improved the sensitivity limit for the DBS samples as it has been previously suggested that RNA extracted from DBS samples can sometimes be fragmented or broken 27, 28 (data not shown). These fingerprick DBS samples were stored at various temperatures during collection, temporary storage until shipment, transportation and storage until processing. Some loss of HIV-1 RNA was even observed in all spiked DBS samples (Table S2) , which were prepared and immediately stored at #80 C after desiccation. This is a common phenomenon with DBS samples in general; furthermore, the degree of HIV-1 RNA loss can also vary depending on the viral RNA extraction technique used, some of which are not suitable for DBS samples. 21, 29 When patients' fingerprick DBS samples were used, an 82.8% amplification success rate was obtained. We found that the remaining 17.2% of patients whose samples failed to amplify probably had a low viral load at the time of sampling. Previously, it has been suggested that DBS samples may be limited for the analysis of viral RNA if the viral load is too low, i.e. less than 1000 HIV-1 RNA copies/mL of plasma. [29] [30] [31] Using spiked DBS samples, we also reached a lower limit of detection at 1000 HIV-1 RNA copies/mL. The lower limit of detection for our patients' DBS samples seemed higher, i.e. 5000 HIV-1 cDNA copies/mL of blood on DBSs. However, these data might be difficult to compare since different assays for the quantification were used and we cannot fully exclude some primer mismatches in some of the failing-to-beamplified samples. Another possible reason for the drop in assay sensitivity seen with patients' fingerprick DBS samples compared with spiked DBS samples is that the spiked DBS samples used for assay development went through more ideal conditions of preparation and storage.
So far, studies on transmitted HIV-1 drug resistance in Cameroon are scarce and have focused on certain parts of the country. [16] [17] [18] For our study sites, no or only very few surveillance data on HIV-1 TDRMs are available and they were obtained more than a decade ago. 32 Our study provides a comprehensive and contemporary description of the prevalence of transmitted HIV-1 drug resistance among newly diagnosed HIV-1 patients in the western and northern parts of Cameroon. By WHO classification, the prevalence is low (,5%) for all three drug classes separately. Mbunkah et al. 
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Low transmitted HIV-1 drug resistance in Cameroon JAC Table 2 . 97 is given for all sites where only the TDRM was detected, since our cut-off for minority HIV-1 drug-resistant variants was set at 3%. Similar results for TDRM frequencies and nucleotide coverage were seen with the PAseq tool (https://www.paseq.org/).
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The overall prevalence we report here is slightly lower than what was reported for the eastern part of the country in 2011. 17 Those authors reported an overall prevalence of 7.8% with many more TDRMs to NRTIs (5.3%) than NNRTIs (1.9%) and PIs (1.9%). According to the WHO HIV drug resistance report for 2017, 4 ,15 levels of any pretreatment HIV drug resistance (PDR) was below 10% in Cameroon. This same report with 321 individuals sampled in 2015 from different hospitals in Cameroon demonstrated comparable findings to ours for their 223 ART-naive individuals, with similar prevalence rates and overlapping confidence intervals for drug resistance to PIs, NRTIs, NNRTIs or any drug class. Our study also saw unequal numbers of participants randomly enrolled from each study site. The hospital in site B is the largest compared with the others and enrolled the highest number of participants in the study. ART was also introduced earlier to this population relative to the other sites. The NNRTI mutation K103N and NRTI mutations M184V/I were most commonly detected in our study population and respectively confer high-level resistance to efavirenz/ nevirapine and lamivudine/emtricitabine, 34 commonly prescribed drugs in Cameroon. It is common to detect these DRMs among patients treated with these drugs and experiencing virological failure, 34 and they can subsequently transmit them. We are also reporting one of the first studies on minority drugresistant HIV-1 variants in ART-naive patients in Cameroon. The fact that the significant difference in the cDNA copy numbers between patients with and without TDRMs became not significant once data from patients with low-abundance TDRMs were excluded is an indication that this latter group of patients were possibly infected for longer periods than the other individuals. Four percent of the patients harboured TDRMs at frequencies between 3% and 15% and mostly against NNRTIs. This is lower than was previously reported in ART-naive patients in Cameroon (17%-20%) 11 at frequencies .1%. Applying our range of 3%-15% to their study population, the prevalence of low-abundance TDRMs would decrease to 1.5%. Another study with NGS data from 32 ART-naive patients with highly diverse subtypes in Cameroon found two minority variants constituting 7% (T215F/Y) and 18% (K103N) of the quasispecies. 35 Although the impact of these minority variants on the success of ART is not clearly known, 36 a substantial number of our ART-naive patients harbour them. This may give rise to the rapid selection of drug-resistant viruses, which can subsequently lead to early therapy failure in treatment-naive patients receiving ART regimens with a low genetic resistance barrier. 6 It has been shown that phylogenetic analysis is a useful tool in identifying clusters of HIV transmission since very related viral sequences may correlate with common social or risk-behaviour patterns in individuals. 37, 38 Although we found no transmitted HIV-1 drug-resistant strains spreading in our study population, a large Swiss survey on transmitted HIV-1 drug resistance conducted between 1996 and 2009 showed that DRMs are frequently transmitted among ART-naive MSM. 39 However, our sampling density is probably considerably lower compared with the Swiss settings.
We observed that having unprotected sex with a known HIV-1-positive person was significantly associated with the transmission of DRMs. These patients had 9.6-fold higher odds of harbouring genotypic drug-resistant HIV-1 strains, suggesting a more advanced disease stage and possible ART experience of the DRM transmitters. One factor we did not evaluate in this study is the patients' history of sexually transmitted diseases. This has been shown in Southern Taiwan to predispose patients to 7.8-fold increased odds of becoming infected with genotypic drug-resistant HIV-1 strains. 40 In conclusion, we have established an assay for HIV-1 drug resistance genotyping based on NGS, applicable to DBS samples and genotyping all heterogeneous HIV-1 subtypes of at least group M with similar sensitivity and specificity to other known DBS assays. [41] [42] [43] The sample type used, the assay's sensitivity and broad subtype coverage make it ideal for HIV-1 drug resistance genotyping in areas with limited resources and a high HIV-1 subtype diversity. Although transmitted HIV-1 drug resistance is currently low in the study sites in Cameroon, continued surveillance is still necessary to detect any changes in drug resistance trends early enough. The evidence of some risky sexual behaviours found in this study depicts a public health problem with possible implications for the prevention of new HIV-1 infections in the country. This information is important for future preventive intervention strategies in the study sites and the whole country at large.
